Aurora-A-mediated Phosphorylation of LKB1 Compromises LKB1/AMPK Signaling Axis to Facilitate NSCLC Growth and Migration

Overview

Journal Oncogene

Specialties Molecular Biology
Oncology

Date 2017 Oct 3

PMID 28967900

Citations 27

Authors

X Zheng

J Chi

J Zhi

H Zhang

D Yue

J Zhao

D Li

Y Li

M Gao

J Guo

Affiliations

Soon will be listed here.

Abstract

Deletion or loss-of-function mutation of LKB1, frequently occurring in non-small cell lung cancers (NSCLCs), is a predominant caution of NSCLC initiation and progression. However, the upstream signaling pathways governing LKB1 activation are largely unknown. Here, we report that LKB1 undergoes Aurora kinase A (AURKA)-mediated phosphorylation, which largely compromises the LKB1/AMPK signaling axis, in turn leading to the elevation of NSCLC cell proliferation, invasion and migration. Mechanically, AURKA-mediated phosphorylation of LKB1 impairs LKB1 interaction with and phosphorylation of its downstream target AMPKα, which has critical roles in governing cancer cell energy metabolic homeostasis and tumorigenesis. Clinically, AURKA displays high levels in NSCLC patients, and correlates with poor outcome of patients with lung adenocarcinoma. Pathologically, the amplification or activation of AURKA-induced impairment of the LKB1/AMPK signaling pathway contributes to NSCLC initiation and progression, highlighting AURKA as a potential therapeutic target for combatting hyperactive AURKA-driven NSCLCs.

Citing Articles

Transcriptomic changes in oxidative stress, immunity, and cancer pathways caused by cannabis vapor on alveolar epithelial cells.

Wilson E, Graham P, Eidelman D, Baglole C Cell Biol Toxicol. 2025; 41(1):57.

PMID: 40056285 PMC: 11890392. DOI: 10.1007/s10565-025-09997-3.

Insights into targeting LKB1 in tumorigenesis.

Trelford C, Shepherd T Genes Dis. 2024; 12(2):101402.

PMID: 39735555 PMC: 11681833. DOI: 10.1016/j.gendis.2024.101402.

The significant others of aurora kinase a in cancer: combination is the key.

Nikhil K, Shah K Biomark Res. 2024; 12(1):109.

PMID: 39334449 PMC: 11438406. DOI: 10.1186/s40364-024-00651-4.

LKB1 biology: assessing the therapeutic relevancy of LKB1 inhibitors.

Trelford C, Shepherd T Cell Commun Signal. 2024; 22(1):310.

PMID: 38844908 PMC: 11155146. DOI: 10.1186/s12964-024-01689-5.

Energy metabolism as the hub of advanced non-small cell lung cancer management: a comprehensive view in the framework of predictive, preventive, and personalized medicine.

Bajinka O, Ouedraogo S, Golubnitschaja O, Li N, Zhan X EPMA J. 2024; 15(2):289-319.

PMID: 38841622 PMC: 11147999. DOI: 10.1007/s13167-024-00357-5.

References

Zakikhani M, Dowling R, Fantus I, Sonenberg N, Pollak M . Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res. 2006; 66(21):10269-73. DOI: 10.1158/0008-5472.CAN-06-1500. View

Katayama H, Sen S . Aurora kinase inhibitors as anticancer molecules. Biochim Biophys Acta. 2010; 1799(10-12):829-39. PMC: 4501772. DOI: 10.1016/j.bbagrm.2010.09.004. View

Guo J, Chakraborty A, Liu P, Gan W, Zheng X, Inuzuka H . pVHL suppresses kinase activity of Akt in a proline-hydroxylation-dependent manner. Science. 2016; 353(6302):929-32. PMC: 5326551. DOI: 10.1126/science.aad5755. View

Patel A, Eaves D, Jessen W, Rizvi T, Ecsedy J, Qian M . Ras-driven transcriptome analysis identifies aurora kinase A as a potential malignant peripheral nerve sheath tumor therapeutic target. Clin Cancer Res. 2012; 18(18):5020-30. PMC: 3902639. DOI: 10.1158/1078-0432.CCR-12-1072. View

Nikonova A, Astsaturov I, Serebriiskii I, Dunbrack Jr R, Golemis E . Aurora A kinase (AURKA) in normal and pathological cell division. Cell Mol Life Sci. 2012; 70(4):661-87. PMC: 3607959. DOI: 10.1007/s00018-012-1073-7. View

Zheng X, Guo J, Yang H, Kanai M, He L, Li Y . Aurora-A is a determinant of tamoxifen sensitivity through phosphorylation of ERα in breast cancer. Oncogene. 2013; 33(42):4985-96. PMC: 4002670. DOI: 10.1038/onc.2013.444. View

Zeqiraj E, Filippi B, Deak M, Alessi D, van Aalten D . Structure of the LKB1-STRAD-MO25 complex reveals an allosteric mechanism of kinase activation. Science. 2009; 326(5960):1707-11. PMC: 3518268. DOI: 10.1126/science.1178377. View

Mahadevan D, Stejskal A, Cooke L, Manziello A, Morales C, Persky D . Aurora A inhibitor (MLN8237) plus vincristine plus rituximab is synthetic lethal and a potential curative therapy in aggressive B-cell non-Hodgkin lymphoma. Clin Cancer Res. 2012; 18(8):2210-9. PMC: 4607283. DOI: 10.1158/1078-0432.CCR-11-2413. View

Carretero J, Medina P, Blanco R, Smit L, Tang M, Roncador G . Dysfunctional AMPK activity, signalling through mTOR and survival in response to energetic stress in LKB1-deficient lung cancer. Oncogene. 2006; 26(11):1616-25. DOI: 10.1038/sj.onc.1209951. View

10.

Pollard J, Mortimore M . Discovery and development of aurora kinase inhibitors as anticancer agents. J Med Chem. 2009; 52(9):2629-51. DOI: 10.1021/jm8012129. View

11.

Ritho J, Arold S, Yeh E . A Critical SUMO1 Modification of LKB1 Regulates AMPK Activity during Energy Stress. Cell Rep. 2015; 12(5):734-42. DOI: 10.1016/j.celrep.2015.07.002. View

12.

Harrington E, Bebbington D, Moore J, Rasmussen R, Ajose-Adeogun A, Nakayama T . VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med. 2004; 10(3):262-7. DOI: 10.1038/nm1003. View

13.

Staff S, Isola J, Jumppanen M, Tanner M . Aurora-A gene is frequently amplified in basal-like breast cancer. Oncol Rep. 2010; 23(2):307-12. View

14.

Marcus A, Zhou W . LKB1 regulated pathways in lung cancer invasion and metastasis. J Thorac Oncol. 2010; 5(12):1883-6. PMC: 2995373. DOI: 10.1097/JTO.0b013e3181fbc28a. View

15.

Al-Khafaji A, Marcus M, Davies M, Risk J, Shaw R, Field J . mRNA expression is an independent predictor of poor prognosis in patients with non-small cell lung cancer. Oncol Lett. 2017; 13(6):4463-4468. PMC: 5452881. DOI: 10.3892/ol.2017.6012. View

16.

Lee S, Li C, Jin G, Cai Z, Han F, Chan C . Skp2-dependent ubiquitination and activation of LKB1 is essential for cancer cell survival under energy stress. Mol Cell. 2015; 57(6):1022-1033. PMC: 5337120. DOI: 10.1016/j.molcel.2015.01.015. View

17.

Ji H, Ramsey M, Hayes D, Fan C, McNamara K, Kozlowski P . LKB1 modulates lung cancer differentiation and metastasis. Nature. 2007; 448(7155):807-10. DOI: 10.1038/nature06030. View

18.

Brose M, Volpe P, Feldman M, Kumar M, Rishi I, Gerrero R . BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res. 2002; 62(23):6997-7000. View

19.

Goos J, Coupe V, Diosdado B, Delis-van Diemen P, Karga C, Belien J . Aurora kinase A (AURKA) expression in colorectal cancer liver metastasis is associated with poor prognosis. Br J Cancer. 2013; 109(9):2445-52. PMC: 3817339. DOI: 10.1038/bjc.2013.608. View

20.

Matulonis U, Sharma S, Ghamande S, Gordon M, Del Prete S, Ray-Coquard I . Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. Gynecol Oncol. 2012; 127(1):63-9. DOI: 10.1016/j.ygyno.2012.06.040. View